Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Koeppen

Showing results (91-100 of 147) with videos related to

Pageof 15
Sort By:
Applied Immunohistochemistry & Molecular Morphology : AIMM|January 19, 2018
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for AtezolizumabBharathi Vennapusa, Brian Baker, Marcin Kowanetz, et al.
Cancer Research|May 1, 2002
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugateSarajane Ross, Susan D Spencer, Ilona Holcomb, et al.
Cancer Immunology, Immunotherapy : CII|December 8, 2017
Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screeningXu-Chao Zhang, Xu Cao, Chun Sun, et al.
Blood|December 4, 2023
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomasStephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, et al.
Nature Communications|December 3, 2025
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinationsTianshi Lu, Habib Hamidi, Mark A Socinski, et al.
Blood|July 28, 2009
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphomaDavid Dornan, Fiona Bennett, Yvonne Chen, et al.
Blood Advances|August 1, 2022
Disruption of stem cell niche-confined R-spondin 3 expression leads to impaired hematopoiesisAntonina V Kurtova, Melanie Heinlein, Simon Haas, et al.
Cancer Research|April 9, 2020
IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor MicroenvironmentJonathan M Harnoss, Adrien Le Thomas, Mike Reichelt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2013
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor modelsJie Lin, Deepak Sampath, Michelle A Nannini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
Pageof 15

Showing results (91-100 of 147) with videos related to

Sort By:
Pageof 15
Applied Immunohistochemistry & Molecular Morphology : AIMM|January 19, 2018
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for AtezolizumabBharathi Vennapusa, Brian Baker, Marcin Kowanetz, et al.
Cancer Research|May 1, 2002
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugateSarajane Ross, Susan D Spencer, Ilona Holcomb, et al.
Cancer Immunology, Immunotherapy : CII|December 8, 2017
Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screeningXu-Chao Zhang, Xu Cao, Chun Sun, et al.
Blood|December 4, 2023
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomasStephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, et al.
Nature Communications|December 3, 2025
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinationsTianshi Lu, Habib Hamidi, Mark A Socinski, et al.
Blood|July 28, 2009
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphomaDavid Dornan, Fiona Bennett, Yvonne Chen, et al.
Blood Advances|August 1, 2022
Disruption of stem cell niche-confined R-spondin 3 expression leads to impaired hematopoiesisAntonina V Kurtova, Melanie Heinlein, Simon Haas, et al.
Cancer Research|April 9, 2020
IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor MicroenvironmentJonathan M Harnoss, Adrien Le Thomas, Mike Reichelt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2013
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor modelsJie Lin, Deepak Sampath, Michelle A Nannini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
Pageof 15